Cholesterol















Lipid Lowering Evidence - Cardiovascular Mortality Reduction:

Optimization of cardiac risk factors and lipid abnormalities can contribute to global cardiovascular morbidity and mortality reduction. The evidence and the cost benefit, particularly in 2° prevention, are compelling. Delays and gaps in implementation compromise patient outcomes and represent a huge lost opportunity to reduce hospitalization and health care costs and diminish the burden of cardiovascular disease.

The clinical benefit of lipid lowering was examined in a meta-analysis of 8 double blind placebo controlled secondary prevention trials up to an including HPS (6) in 54,381 subjects treated with simvastatin, pravastatin, lovastatin or fluvastatin (8) Compared to placebo a mean 20% cholesterol reduction was associated with a 30% reduction in CHD events and a 17% reduction in all cause mortality. The principal secondary prevention trials, 4S (3), CARE (4), and LIPID (5) enrolled patients to a maximum age of 75 years. Patients > 65 years old had similar benefits as compared to younger patients.


Return to Top

 

  Version 2.0, June 2004
This site complies to the HONcode standard for trustworthy health
information: verify here.

 

WOSCOP AF-CAPS LIPID HPS PROSPER ALLHAT PROSPER HPS CARE 4-S AF-CAPS WOSCOP ASCOT 4S CARE ALLHAT ASCOT REVERSAL PROVE-IT CARDS REVERSAL PROVE-IT CARDS